ClinicalTrials.gg
CompletedNCT02417064TRANSFORM-1Updated Apr 29, 2025Results posted

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Phase 3 interventional study of Esketamine and Placebo in Treatment-resistant Depression, sponsored by Janssen Research & Development, LLC. Completed at 92 sites in 9 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.

Enrollment
7th of 18
346 · median 210
Started
2015
with 4 others
Phase 3
11 of 18
2 open now
Registered
3rd of 18
by date
Lead sponsor
11 of 18
Janssen Research & Development, LLC

Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 7th largest by enrollment, is one of 5 that started in 2015, is one of 11 in phase 3, and was the 3rd registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.

Read the detailed description

This is a randomized, double-blind (neither the researchers nor the participants know what treatment the participant is receiving), active-controlled, multicenter study (more than 1 study site) in participants with TRD to assess the efficacy, safety, and tolerability of fixed doses of intranasal esketamine plus a newly initiated oral antidepressant compared with a newly initiated oral antidepressant (active comparator) plus intranasal placebo. The study will consist of 3 phases: Screening/Prospective Observational Phase (4-7 weeks), Double-blind Induction Phase (4-weeks), Follow-up Phase (24-weeks). Participants who rollover into a long-term maintenance study will not participate in the Follow-up Phase. At the start of the screening/prospective observational phase, the participant must have had documented non-response to at least 1 antidepressant treatment (based on Massachusetts General Hospital - Antidepressant Treatment Response Questionnair [MGH-ATRQ]) in the current episode of depression, and participant is taking a different oral antidepressant treatment on the MGH-ATRQ for at least the previous 2 weeks at or above the minimum therapeutic dose. This antidepressant treatment, as well as any other ongoing medications being taken for depression at screening (including adjunctive/ augmentation therapies), will continue from the start of Week 1 through the end of Week 4 of the screening/prospective observational phase. Participants will be randomly assigned to receive Intranasal esketamine (56 milligrams [mg]), Intranasal esketamine (84 mg), or Intranasal placebo. In addition, each participant will be assigned to receive 1 of 4 oral antidepressant medications from 2 different classes of antidepressant treatments, a Selective Serotonin Reuptake Inhibitor (SSRI) (escitalopram or sertraline) or a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) (duloxetine or venlafaxine extended release [XR]), initiated on Day 1 and continued through the double-blind induction phase. Participants will be primarily evaluated for improvement in depressive symptoms as assessed by change in Montgomery-Asberg Depression Rating Scale (MADRS) total score at Week 4. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Treatment-resistant Depression

Keywords

  • Treatment-resistant Depression
  • Esketamine
  • Placebo
  • Oral Antidepressant
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of signing the form (ICF), participant must be a man or woman 18 (or older if the minimum legal age of consent in the country in which the study is taking place is greater than [>]18) to 64 years of age, inclusive
  • At the start of the screening/prospective observational phase, participant must meet the (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) (if single-episode MDD, the duration must be greater than or equal to [>=] 2 years) or recurrent MDD, without psychotic features, based upon clinical assessment and confirmed by the Mini-International Neuropsychiatric Interview (MINI)
  • At the start of the screening/prospective observational phase, participant must have an Inventory of Depressive Symptomatology-Clinician rated ( IDS-C30) total score of greater than or equal to (>=) 34
  • At the start of the screening/prospective observational phase, participants must have had non-response (less than or equal to [\<=25] percent [%] improvement) to >=1 but less than or equal to (\<=) 5 (if current episode is >2 years, upper limit is applicable to only the last 2 years) oral antidepressant treatments taken at adequate dosage and for adequate duration, as assessed using the Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and documented by medical history and pharmacy/prescription records, for the current episode of depression.

Participant is taking a different oral antidepressant treatment on the MGH-ATRQ for at least the previous 2 weeks at or above the minimum therapeutic dose

  • The participant's current major depressive episode, depression symptom severity (Week 1 MADRS total score >=28 required), and antidepressant treatment response in the current depressive episode, must be confirmed using a Site Independent Qualification Assessment

Exclusion criteria

Exclusion Criteria:

  • Participants who have previously demonstrated nonresponse of depressive symptoms to esketamine or ketamine in the current major depressive episode, to all 4 of the oral antidepressant treatment options available for the double-blind induction phase (i.e, duloxetine, escitalopram, sertraline, and venlafaxine extended release [XR]) in the current major depressive episode (based on MGH-ATRQ), or an adequate course of treatment with electroconvulsive therapy (ECT) in the current major depressive episode, defined as at least 7 treatments with unilateral/bilateral ECT
  • Participant has received vagal nerve stimulation (VNS) or has received deep brain stimulation (DBS) in the current episode of depression
  • Participant has a current or prior diagnosis of a psychotic disorder or MDD with psychotic features bipolar or related disorders (confirmed by the MINI), obsessive compulsive disorder (current only), intellectual disability (DSM-5 diagnostic codes 317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline personality disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder
  • Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening/prospective observational phase, per the investigator's clinical judgment or based on the Columbia Suicide Severity Rating Scale (C-SSRS)
  • Participants with history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
346 participants (actual)

Study arms

  • Experimental
    Intranasal Esketamine 84mg plus Oral Antidepressant

    As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.

    Drug: Esketamine · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

  • Experimental
    Esketamine 56 mg plus Oral Antidepressant

    Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.

    Drug: Esketamine · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

  • Active comparator
    Placebo plus Oral Antidepressant

    Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.

    Drug: Placebo · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

Interventions

  • Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.

  • DrugPlacebo

    Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.

  • Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).

  • Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.

  • Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.

  • Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis

    MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: Baseline up to Day 28 of Double-blind Induction Phase

  2. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

    MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using Last Observation Carried Forward (LOCF) method and last post baseline observation during double-blind induction phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

Secondary outcomes

  1. Percentage of Participants With Onset of Clinical Response by Day 2 and Day 8

    A participant was defined as having a clinical response if there was at least 50% improvement (decrease) from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, however score must show at least 25% improvement. Participants who did not meet these criteria or discontinued during the study before Day 28 were considered as non-responders and were assigned the value of 0 (that is no). MADRS is clinician-rated scale that consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), for total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: Day 2 up to Day 28 and Day 8 up to Day 28

  2. Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis

    The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired), where higher score indicates greater impairment.

    Time frame: Baseline up to Day 28 of Double-blind Induction phase

  3. Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

    The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired) where higher score indicates greater impairment. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

  4. Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis

    PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks.

    Time frame: Baseline up to Day 28 of Double-blind Induction phase

  5. Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

    PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

  6. Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)

    A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: At Day 28 of Double-blind Induction phase

  7. Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)

    A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

    Time frame: At Day 28 (Double-blind Endpoint)

  8. Percentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)

    Participants who had a MADRS total score of less than or equal to (\<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: At Day 28 of Double-blind Induction Phase

  9. Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)

    Participants who had a MADRS total score of less than or equal to (\<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

    Time frame: At Day 28 (Double-blind Endpoint)

  10. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])

    CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients (a decrease in score indicates improvement). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

  11. Change From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])

    GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants responded to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Double-blind Endpoint (Day 28)

  12. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index

    EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health).

    Time frame: Baseline up to End of Double-blind Induction Phase (Day 28)

  13. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS

    EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).

    Time frame: Baseline up to end of Double-blind induction phase (Day 28)

  14. Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score

    EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

    Time frame: Baseline up to end of Double-blind Induction phase (Day 28)

07

Results

Posted Apr 18, 2019
Limitations and caveats
Transient, dissociative effects of esketamine are difficult to blind, site staff who observed treatment sessions could have been biased. To ensure unbiased efficacy evaluations, independent, remote, blinded MADRS raters assessed treatment response.

Participant flow

Double-blind Induction Phase (4 Weeks)
Participant flow — Double-blind Induction Phase (4 Weeks)
MilestoneIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Started117116113
Full analysis set (fas)115114113
Safety analysis set115116113
Completed11197107
Not completed6196
Withdrew: Adverse event172
Withdrew: Lack of efficacy110
Withdrew: Lost to follow-up010
Withdrew: Protocol violation211
Withdrew: Withdrawal by subject151
Withdrew: Other142
Follow-up Phase (24 Weeks)
Participant flow — Follow-up Phase (24 Weeks)
MilestoneIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Started475269
Completed81018
Not completed394251
Withdrew: Lost to follow-up021
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject392
Withdrew: Pi decision342944
Withdrew: Other223

Outcome measures

PrimaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis

MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
Baseline up to Day 28 of Double-blind Induction Phase
Reported as:
Mean · Units on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis-19.0 ± 13.86-18.8 ± 14.12-14.8 ± 15.07
Statistical analysis
  • Intranasal Esketamine 84 mg Plus Oral AD vs Oral AD Plus Intranasal Placebo · Mixed Model for Repeated Measures · p = 0.088 · Difference of least square (ls) means: -3.2 · 95% CI -6.88 to 0.45
  • Intranasal Esketamine 56 mg Plus Oral Antidepressant vs Oral AD Plus Intranasal Placebo · Difference of least square (ls) means: -4.1 · 95% CI -7.67 to -0.49
PrimaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using Last Observation Carried Forward (LOCF) method and last post baseline observation during double-blind induction phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis-18.3 ± 14.21-17.4 ± 14.25-14.3 ± 15.00
Statistical analysis
  • Intranasal Esketamine 84 mg Plus Oral AD vs Oral AD Plus Intranasal Placebo · ANCOVA · p = = 0.250 · Difference of least square (ls) means: -2.0 · 95% CI -5.52 to 1.42
  • Intranasal Esketamine 56 mg Plus Oral Antidepressant vs Oral AD Plus Intranasal Placebo · Difference of least square (ls) means: -4.1 · 95% CI -7.53 to -0.6
SecondaryPercentage of Participants With Onset of Clinical Response by Day 2 and Day 8

A participant was defined as having a clinical response if there was at least 50% improvement (decrease) from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, however score must show at least 25% improvement. Participants who did not meet these criteria or discontinued during the study before Day 28 were considered as non-responders and were assigned the value of 0 (that is no). MADRS is clinician-rated scale that consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), for total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
Day 2 up to Day 28 and Day 8 up to Day 28
Reported as:
Number · Percentage of Participants
Percentage of Participants With Onset of Clinical Response by Day 2 and Day 8
Percentage of ParticipantsIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Day 2 up to Day 2810.48.81.8
Day 8 up to Day 2813.011.43.5
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis

The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired), where higher score indicates greater impairment.

Time frame:
Baseline up to Day 28 of Double-blind Induction phase
Reported as:
Mean · Units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis-11.0 ± 9.32-11.1 ± 10.04-8.4 ± 9.70
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1) work/school, 2) social life, and 3) family life/home responsibilities using 0 (not at all) to 10 (extremely) rating scale. Score for first 3 items are summed to create total score of 0 (unimpaired) to 30 (highly impaired) where higher score indicates greater impairment. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis-10.7 ± 9.39-10.2 ± 10.00-8.1 ± 9.57
SecondaryChange From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis

PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks.

Time frame:
Baseline up to Day 28 of Double-blind Induction phase
Reported as:
Mean · Units on a scale
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis-11.0 ± 8.07-11.7 ± 7.74-9.1 ± 8.35
SecondaryChange From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

PHQ-9 is 9-item, self-reported scale assessing 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria. Each item is rated on 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half days, 3 = Nearly every day). The scores are summed for a total score ranging from 0-27. Higher score indicates greater severity of depression. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The recall period is 2 weeks. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis-10.9 ± 8.26-10.9 ± 7.81-8.9 ± 8.37
SecondaryPercentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)

A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
At Day 28 of Double-blind Induction phase
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)
Percentage of ParticipantsIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at Day 28 of Double-blind Induction Phase (Observed Data)54.153.138.9
SecondaryPercentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)

A participant was defined as a responder (yes=1 and no=0) at a given time point if the percent reduction from baseline in MADRS total score is at least 50 percent (%). The percentage of participants who achieved at least 50% reduction from baseline were reported. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

Time frame:
At Day 28 (Double-blind Endpoint)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)
Percentage of ParticipantsIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Percentage of Participants Who Achieved at Least 50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28]) (LOCF Data)53.047.837.2
SecondaryPercentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)

Participants who had a MADRS total score of less than or equal to (\<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
At Day 28 of Double-blind Induction Phase
Reported as:
Number · Percentage of participants
Percentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)
Percentage of participantsIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Percentage of Participants in Remission (MADRS<=12) at Day 28 of Double-blind Induction Phase (Observed Data)3638.830.6
SecondaryPercentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)

Participants who had a MADRS total score of less than or equal to (\<=) 12 were considered as remitters. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

Time frame:
At Day 28 (Double-blind Endpoint)
Reported as:
Number · Percentage of participants
Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)
Percentage of participantsIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis (LOCF Data)34.835.429.2
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])

CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients (a decrease in score indicates improvement). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Median · Units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score up to Endpoint (Double-blind Induction Phase [Day 28])-2.0 (-5 to 1)-2.0 (-5 to 1)-1.0 (-6 to 3)
SecondaryChange From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])

GAD-7 is a brief and validated 7-item self-reported assessment of overall anxiety. Participants responded to each item using a 4 point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15-21). Missing data was imputed using LOCF method and the last post baseline observation during the double-blind induction phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Double-blind Endpoint (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in Generalized Anxiety Disorder-7 Item (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])-7.4 ± 5.94-7.7 ± 5.72-6.0 ± 6.01
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index

EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health).

Time frame:
Baseline up to End of Double-blind Induction Phase (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Health Status Index0.224 ± 0.24810.243 ± 0.23950.181 ± 0.2495
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS

EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).

Time frame:
Baseline up to end of Double-blind induction phase (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): EQ-VAS20.9 ± 25.0419.1 ± 26.8614.9 ± 27.15
SecondaryChange From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score

EQ-5D-5L measures health outcome self-completed by respondents. It consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). The descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each has 5 levels (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses are used to generate Health Status Index (HSI). HSI range is -0.148 to 0.949, is anchored at 0 (dead) and 1 (full health). EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

Time frame:
Baseline up to end of Double-blind Induction phase (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score
Units on a scaleIntranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal Placebo
Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) up to End of Double-blind Induction Phase (Day 28): Sum Score-19.0 ± 18.84-19.4 ± 18.43-14.6 ± 19.78

Adverse events

Collected over Up to follow up phase (Week 24). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Phase: Intranasal Esk 56 mg + Oral AD0/115 (0%)2/115 (1.7%)93/115 (80.9%)
DB Phase: Intranasal Esk 84 mg + Oral AD0/116 (0%)0/116 (0%)92/116 (79.3%)
DB Phase: Oral AD + Intranasal Placebo0/113 (0%)0/113 (0%)64/113 (56.6%)
FU Phase: Intranasal Esk 56 mg + Oral AD0/47 (0%)2/47 (4.3%)7/47 (14.9%)
FU Phase: Intranasal Esk 84 mg + Oral AD0/52 (0%)2/52 (3.8%)4/52 (7.7%)
FU Phase: Oral AD + Intranasal Placebo0/69 (0%)1/69 (1.4%)7/69 (10.1%)
Most frequent serious events
Most frequent serious events
EventDB Phase: Intranasal Esk 56 mg + Oral ADDB Phase: Intranasal Esk 84 mg + Oral ADDB Phase: Oral AD + Intranasal PlaceboFU Phase: Intranasal Esk 56 mg + Oral ADFU Phase: Intranasal Esk 84 mg + Oral ADFU Phase: Oral AD + Intranasal Placebo
DepressionPsychiatric disorders1/1150/1160/1132/471/520/69
AnxietyPsychiatric disorders0/1150/1160/1130/471/520/69
InsomniaPsychiatric disorders0/1150/1160/1130/471/520/69
Suicidal IdeationPsychiatric disorders0/1150/1160/1130/470/521/69
HeadacheNervous system disorders1/1150/1160/1130/470/520/69
Most frequent other events
Showing 10 of 28
Most frequent other events
EventDB Phase: Intranasal Esk 56 mg + Oral ADDB Phase: Intranasal Esk 84 mg + Oral ADDB Phase: Oral AD + Intranasal PlaceboFU Phase: Intranasal Esk 56 mg + Oral ADFU Phase: Intranasal Esk 84 mg + Oral ADFU Phase: Oral AD + Intranasal Placebo
NauseaGastrointestinal disorders31/11537/11612/1132/471/521/69
DizzinessNervous system disorders32/11526/11610/1130/471/521/69
DissociationPsychiatric disorders30/11532/1164/1130/470/520/69
VertigoEar and labyrinth disorders24/11524/1162/1130/470/520/69
SomnolenceNervous system disorders24/11521/11613/1130/470/520/69
HeadacheNervous system disorders23/11524/11619/1134/472/523/69
DysgeusiaNervous system disorders17/11520/11617/1130/470/520/69
ParaesthesiaNervous system disorders19/11511/1163/1130/470/520/69
Hypoaesthesia OralGastrointestinal disorders16/11512/1162/1130/470/520/69
HypoaesthesiaNervous system disorders14/11516/1162/1130/471/520/69

Baseline characteristics

The safety analysis set included all randomized participants who received at least 1 dose of intranasal study medication or 1 dose of oral antidepressant medication during the double-blind induction phase.

Age, Categorical
Age, Categorical(Participants)Intranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal PlaceboTotal
<=18 years0112
Between 18 and 65 years115115112342
>=65 years0000
Age, Continuous
Age, Continuous(years)Intranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal PlaceboTotal
Mean46.4 ± 11.1845.7 ± 11.0246.8 ± 11.3646.3 ± 11.16
Sex: Female, Male
Sex: Female, Male(Participants)Intranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal PlaceboTotal
Female818081242
Male343632102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal PlaceboTotal
Hispanic or Latino33273191
Not Hispanic or Latino748071225
Unknown or Not Reported891128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Intranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal PlaceboTotal
American Indian or Alaska Native0101
Asian2125
Black or African American78520
White918686263
More than one race8111130
Unknown or Not Reported79925
Region of Enrollment
Region of Enrollment(Participants)Intranasal Esketamine 56 mg Plus Oral AntidepressantIntranasal Esketamine 84 mg Plus Oral ADOral AD Plus Intranasal PlaceboTotal
Belgium891229
Brazil20191857
Canada77620
Estonia34310
France11101031
Hungary3216
Mexico14161545
Slovakia43310
United States454645136
08

Study locations

92 sites
  • Birmingham, Alabama, United States
  • Little Rock, Arkansas, United States
  • Garden Grove, California, United States
  • Orange, California, United States
  • San Diego, California, United States
  • San Marcos, California, United States
  • San Rafael, California, United States
  • Bradenton, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Chicago, Illinois, United States
  • Hoffman Estates, Illinois, United States
  • Maywood, Illinois, United States
  • Schaumburg, Illinois, United States
  • Wichita, Kansas, United States
  • Gaithersburg, Maryland, United States
  • Boston, Massachusetts, United States
  • Quincy, Massachusetts, United States
  • Watertown, Massachusetts, United States
  • Worcester, Massachusetts, United States
  • Minneapolis, Minnesota, United States
  • O'Fallon, Missouri, United States
  • Saint Charles, Missouri, United States
  • Omaha, Nebraska, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Dayton, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Media, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Lincoln, Rhode Island, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Woodstock, Vermont, United States
  • Bothell, Washington, United States
  • Middleton, Wisconsin, United States
  • Aalst, Belgium
  • Brugge, Belgium
  • Brussel, Belgium
  • Bruxelles, Belgium
  • Gent, Belgium
  • Hasselt, Belgium
  • Heusden-Zolder, Belgium
  • Liège, Belgium
  • Spa, Belgium
  • Yvoir, Belgium
  • Belo Horizonte, Brazil
  • Curitiba, Brazil
  • Fortaleza, Brazil
  • Passo Fundo, Brazil
  • Porto Alegre, Brazil
  • Rio de Janeiro, Brazil
  • Santo André, Brazil
  • Calgary, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Kingston, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • Parnu, Estonia
  • Tallinn, Estonia
  • Tartu, Estonia
  • BESANCON Cedex, France
  • Clermont Ferrand, France
  • Douai, France
  • Issy-les-Moulineaux, France
  • La Tronche, France
  • Lille, France
  • Limoges, France
  • Montpellier Cedex 5, France
  • Nantes, France
  • Neuilly sur Marne, France
  • Nimes Cedex 9, France
  • Paris, France
  • Poitiers, France
  • Toulon, France
  • TOURS cedex 9, France
  • Budapest, Hungary
  • Vác, Hungary
  • Guadalajara, Mexico
  • Leon, Mexico
  • Mazatlan, Mexico
  • Mexico City, Mexico
  • Monterrey, Mexico
  • San Luis Potosi, Mexico
  • San Luis Potosí, Mexico
  • Bratislava, Slovakia
  • Liptovsky Mikulas, Slovakia
  • Rimavska Sobota, Slovakia
  • Roznava, Slovakia
  • Svidnik, Slovakia
09

References and documents

Publications

  • Jha MK, Williamson DJ, Magharehabed G, Turkoz I, Daly EJ, Trivedi MH. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability. J Affect Disord. 2023 Jan 15;321:153-160. doi: 10.1016/j.jad.2022.10.020. Epub 2022 Oct 20. PubMed 36273682 ↗
  • Chen G, Chen L, Zhang Y, Li X, Lane R, Lim P, Daly EJ, Furey ML, Fedgchin M, Popova V, Singh JB, Drevets WC. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2022 Apr 19;25(4):269-279. doi: 10.1093/ijnp/pyab084. PubMed 35022754 ↗
  • Jones RR, Freeman MP, Kornstein SG, Cooper K, Daly EJ, Canuso CM, Nicholson S. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Arch Womens Ment Health. 2022 Apr;25(2):313-326. doi: 10.1007/s00737-021-01185-6. Epub 2022 Jan 1. PubMed 34973081 ↗
  • Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. PubMed 34510411 ↗
  • Turkoz I, Daly E, Singh J, Lin X, Tymofyeyev Y, Williamson D, Salvadore G, Nash AI, Macaluso M, Wilkinson ST, Nelson JC. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies. J Clin Psychiatry. 2021 Jul 20;82(4):20m13800. doi: 10.4088/JCP.20m13800. PubMed 34288609 ↗
  • Doty RL, Popova V, Wylie C, Fedgchin M, Daly E, Janik A, Ochs-Ross R, Lane R, Lim P, Cooper K, Melkote R, Jamieson C, Singh J, Drevets WC. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. CNS Drugs. 2021 Jul;35(7):781-794. doi: 10.1007/s40263-021-00826-9. Epub 2021 Jul 7. PubMed 34235612 ↗
  • Perez-Ruixo C, Rossenu S, Zannikos P, Nandy P, Singh J, Drevets WC, Perez-Ruixo JJ. Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clin Pharmacokinet. 2021 Apr;60(4):501-516. doi: 10.1007/s40262-020-00953-4. Epub 2020 Oct 31. PubMed 33128208 ↗
  • Katz EG, Hough D, Doherty T, Lane R, Singh J, Levitan B. Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Clin Pharmacol Ther. 2021 Feb;109(2):536-546. doi: 10.1002/cpt.2024. Epub 2020 Oct 13. PubMed 32860422 ↗
  • Saad Z, Hibar D, Fedgchin M, Popova V, Furey ML, Singh JB, Kolb H, Drevets WC, Chen G. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials. Int J Neuropsychopharmacol. 2020 Dec 3;23(9):549-558. doi: 10.1093/ijnp/pyaa030. PubMed 32367114 ↗
  • Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630. doi: 10.1093/ijnp/pyz039. PubMed 31290965 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Feb 2018, 30 months.

Results were first posted in Apr 2019, 1 year 1 month after primary completion. A results delay was requested in Dec 2018.

Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2015
First posted
Apr 15, 2015
StartActual
Aug 10, 2015
Primary completionActual
Feb 20, 2018
CompletionActual
Feb 20, 2018
Results delay requested
Dec 10, 2018
Results first posted
Apr 18, 2019
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02417064
Responsible party
Sponsor
First posted
Apr 15, 2015
Start date
Aug 10, 2015
Primary completion
Feb 20, 2018
Completion
Feb 20, 2018
Results posted
Apr 18, 2019
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion